Insight

Latest California Healthline Stories

KHN’s ‘What the Health?’: The Senate Acts

The U.S. Senate worked well into its scheduled August recess to pass a bipartisan infrastructure bill and a budget blueprint that outlines a much larger bill — covering key health priorities — to be written this fall. Meanwhile, the latest surge of covid is making both employers and schools rethink their opening plans. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Yasmeen Abutaleb of The Washington Post join KHN’s Julie Rovner to discuss these issues and more. Also, for “extra credit,” the panelists suggest their favorite health policy stories of the week they think you should read, too.

Apple Aims to Push More Patient Data to Doctors. But Who Can Gauge Its Impact on Health?

The Silicon Valley giant has been cryptic about its plan for the growing mound of health data available through its iPhones and watches. Health systems have experimented with the company’s health app, but it hasn’t yet become central to treatment.

Déjà Vu? Consumers Scramble for Covid Tests in Hard-Hit Areas

As the nation confronts the delta variant, many consumers are again facing delays getting tested. The problem appears most acute in the South and Midwest, where new infections are growing the fastest, but Californians are also encountering bottlenecks.

KHN’s ‘What the Health?’: Delta Blues

Covid is back with a vengeance, with some people clamoring for booster shots while others harden their resistance to getting vaccinated at all. Meanwhile, the Food and Drug Administration is pushing hard on drugmaker Pfizer’s request to upgrade the emergency authorization for its vaccine and give it final approval. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, for “extra credit,” the panelists suggest their favorite health policy stories of the week they think you should read, too.

2+2=? Senate Uses Murky Math as It Shelves Drug Pricing Rule to Fund Infrastructure

The Medicare rule, designed by the Trump administration to take money away from drug industry brokers and provide refunds to patients, has not been implemented. But budget analysts say if it were, it would cost the government money. So senators are pushing the rule aside and claiming to save billions of dollars, which they want to use instead on new projects.